Activation of platelets in bronchial asthma

Area of Science:

• Immunology
• Hematology
• Pulmonology

Background:

• Asthma is a chronic inflammatory disease of the airways.
• Platelet activation and mediator release may play a role in asthma pathogenesis.
• Theophylline is a bronchodilator with potential anti-inflammatory effects.

Purpose of the Study:

• To determine if platelets are activated in asthmatics.
• To investigate the release of preformed mediators from activated platelets in asthma.
• To assess the effect of oral theophylline on platelet activation in asthmatics.

Main Methods:

• Compared intracellular calcium concentration ([Ca2+]i), CD62P expression, and RANTES levels in platelets.
• Studied three groups: normal subjects, asthmatics without medication, and asthmatics on theophylline.
• Stimulated platelets with thrombin or STA2 in the absence of external calcium.

Main Results:

• Asthmatics (without theophylline) showed significantly higher [Ca2+]i, CD62P expression, and RANTES release after stimulation compared to normal subjects and theophylline-treated asthmatics.
• Platelet activation markers were elevated in untreated asthmatics.
• Theophylline administration suppressed these markers of platelet activation.

Conclusions:

• Platelet activation is enhanced in asthmatics, leading to increased release of chemokines like RANTES.
• Oral theophylline can suppress this agonist-mediated platelet activation.
• These findings suggest a potential therapeutic role for theophylline in managing asthma-related platelet dysfunction.